Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: GlobeNewswire
SAN MATEO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual investor and analyst day on Friday, May 3, 2024 at 12:30 PM ET. To register, click here. The event will feature Stephen Harrison, MD (Visiting Professor of Hepatology at Radcliffe Department of Medicine, University of Oxford) who will discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH). It will also include a discussion on the Company's lead drug candidate, denifanstat, an oral, once-daily pill and selective FASN inhibitor and the recent positive Phase 2b FASCINATE-2 data evaluating denifanstat in MASH. A live question and answer session will follow the formal presentation. About Stephen Harrison, MD S
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024GlobeNewswire
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial OfficerGlobeNewswire
- Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $32.00 price target on the stock.MarketBeat
- Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity [Seeking Alpha]Seeking Alpha
SGMT
Sec Filings
- 5/8/24 - Form 4
- 5/8/24 - Form 3
- 5/6/24 - Form 8-K
- SGMT's page on the SEC website